FDA "Drug Watch": Companies Will Have No Input On Content Prior To Posting
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors will be notified before products are listed on FDA's drug safety website but will not be given an opportunity to comment on the information ahead of time, Office of New Drugs Director Jenkins says. FDA will be "cautious" regarding the extrapolation of individual product data across a class.
You may also be interested in...
FDA Drug Safety Board May Ask Sponsors To Present At Meetings
“There’s real potential value” to allowing sponsors to present at Drug Safety Oversight Board meetings, board Executive Director Cummins says. Sponsors will not be able to provide input on information to be placed on Drug Watch prior to posting.
FDA Drug Safety Board May Ask Sponsors To Present At Meetings
“There’s real potential value” to allowing sponsors to present at Drug Safety Oversight Board meetings, board Executive Director Cummins says. Sponsors will not be able to provide input on information to be placed on Drug Watch prior to posting.
FDA “Drug Watch” Early Warnings Will Have Lasting Negative Effect, PhRMA Says
A “Drug Watch” listing can do lasting damage to a brand’s reputation based on inadequate data, PhRMA Chief Medical Officer Antony says. The PhRMA exec uses an “extreme” example to highlight his point: imagine “someone reporting that they had early information that you may be a child molester.”